Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Endocrine
Erschienen in: Endocrine 1/2022

15.01.2022 | Original Article

Relationship between the ApoB/ApoA-I ratio trajectory and risk of type 2 diabetes in China: a retrospective cohort study

verfasst von: Tengfei Yang, Bo Zhao, Dongmei Pei

Erschienen in: Endocrine | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Little research has investigated the correlation of changes in long-term apolipoprotein B/apolipoprotein A-I (ApoB/ApoA-I) ratio with risk of new-onset type 2 diabetes (T2D) among ordinary people. Therefore, the research took long-term ApoB/ApoA-I ratio trajectories as independent variables for exploring their association with the risk of newly diagnosed T2D.

Methods

Altogether 5362 non-diabetic participants with a median age of 49 were enrolled in the cohort study. Their ApoB/ApoA-I ratio trajectories from 2016 to 2019 were analyzed and grouped using group-based trajectory modeling. The Kaplan–Meier approach was employed for calculating the newly diagnosed T2D-related incidence with different ApoB/ApoA-I ratio trajectories. A log-rank test was conducted for testing the presence of statistical difference in new-onset T2D incidence among the different ApoB/ApoA-I ratio trajectory groups. A multivariate Cox proportional hazards regression model was adopted for analyzing how ApoB/ApoA-I ratio trajectory changes affected new-onset T2D.

Results

From 2016 to 2019, 199 patients developed T2D (3% in 3 years). The incidence of T2D was 2.0%, 3.28%, 5.86%, and 6.92% for low, middle, upper, and high ApoB/ApoA-I ratio trajectories, respectively. Following adjustment of underlying confounding factors, in contrast to low ApoB/ApoA-I ratio trajectory, new-onset T2D risk ratios and hazard ratio (HR) (95% confidence intervals [CI]) for the middle lower ApoB/ApoA-I ratio trajectory, and upper middle and high ApoB/ApoA-I ratio trajectories were [HR (95% CI)] 1.35(0.88–2.08), 1.98(1.27–3.09) and 2.42(1.35–4.34), respectively, indicating high and statistically significant risks of T2D.

Conclusion

Variations of the ApoB/ApoA-I ratio trajectory exerted independent effects on the 3-year incidence of T2D. Long-term monitoring on the ApoB/ApoA-I ratio locus may help improve the identification on patients with T2D.
Literatur
1.
P. Saeedi, I. Petersohn, P. Salpea, B. Malanda, S. Karuranga, N. Unwin, S. Colagiuri, L. Guariguata, A.A. Motala, K. Ogurtsova, J.E. Shaw, D. Bright, R. Williams, Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res. Clin. Pract. 157, 107843 (2019)CrossRef
2.
Y. Li, D. Teng, X. Shi, G. Qin, Y. Qin, H. Quan, B. Shi, H. Sun, J. Ba, B. Chen, J. Du, L. He, X. Lai, Y. Li, H. Chi, E. Liao, C. Liu, L. Liu, X. Tang, N. Tong, G. Wang, J.A. Zhang, Y. Wang, Y. Xue, L. Yan, J. Yang, L. Yang, Y. Yao, Z. Ye, Q. Zhang, L. Zhang, J. Zhu, M. Zhu, G. Ning, Y. Mu, J. Zhao, W. Teng, Z. Shan, Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ 369, m997 (2020)CrossRef
3.
Tian Hongyang, G.U. Chengying, General practitioners need to know progress in the management of type 2 diabetes. Shanghai Pharm. 41, 9–17 (2020). 62
4.
T. Vos, A.D. Flaxman, M. Naghavi, R. Lozano, C. Michaud, M. Ezzati, K. Shibuya, J.A. Salomon, S. Abdalla, V. Aboyans, J. Abraham, I. Ackerman, R. Aggarwal, S.Y. Ahn, M.K. Ali, M. Alvarado, H.R. Anderson, L.M. Anderson, K.G. Andrews, C. Atkinson, L.M. Baddour, A.N. Bahalim, S. Barker-Collo, L.H. Barrero, D.H. Bartels, M.G. Basáñez, A. Baxter, M.L. Bell, E.J. Benjamin, D. Bennett, E. Bernabé, K. Bhalla, B. Bhandari, B. Bikbov, A. Bin Abdulhak, G. Birbeck, J.A. Black, H. Blencowe, J.D. Blore, F. Blyth, I. Bolliger, A. Bonaventure, S. Boufous, R. Bourne, M. Boussinesq, T. Braithwaite, C. Brayne, L. Bridgett, S. Brooker, P. Brooks, T.S. Brugha, C. Bryan-Hancock, C. Bucello, R. Buchbinder, G. Buckle, C.M. Budke, M. Burch, P. Burney, R. Burstein, B. Calabria, B. Campbell, C.E. Canter, H. Carabin, J. Carapetis, L. Carmona, C. Cella, F. Charlson, H. Chen, A.T. Cheng, D. Chou, S.S. Chugh, L.E. Coffeng, S.D. Colan, S. Colquhoun, K.E. Colson, J. Condon, M.D. Connor, L.T. Cooper, M. Corriere, M. Cortinovis, K.C. de Vaccaro, W. Couser, B.C. Cowie, M.H. Criqui, M. Cross, K.C. Dabhadkar, M. Dahiya, N. Dahodwala, J. Damsere-Derry, G. Danaei, A. Davis, D. De Leo, L. Degenhardt, R. Dellavalle, A. Delossantos, J. Denenberg, S. Derrett, D.C. Des Jarlais, S.D. Dharmaratne, M. Dherani, C. Diaz-Torne, H. Dolk, E.R. Dorsey, T. Driscoll, H. Duber, B. Ebel, K. Edmond, A. Elbaz, S.E. Ali, H. Erskine, P.J. Erwin, P. Espindola, S.E. Ewoigbokhan, F. Farzadfar, V. Feigin, D.T. Felson, A. Ferrari, C.P. Ferri, E.M. Fèvre, M.M. Finucane, S. Flaxman, L. Flood, K. Foreman, M.H. Forouzanfar, F.G. Fowkes, R. Franklin, M. Fransen, M.K. Freeman, B.J. Gabbe, S.E. Gabriel, E. Gakidou, H.A. Ganatra, B. Garcia, F. Gaspari, R.F. Gillum, G. Gmel, R. Gosselin, R. Grainger, J. Groeger, F. Guillemin, D. Gunnell, R. Gupta, J. Haagsma, H. Hagan, Y.A. Halasa, W. Hall, D. Haring, J.M. Haro, J.E. Harrison, R. Havmoeller, R.J. Hay, H. Higashi, C. Hill, B. Hoen, H. Hoffman, P.J. Hotez, D. Hoy, J.J. Huang, S.E. Ibeanusi, K.H. Jacobsen, S.L. James, D. Jarvis, R. Jasrasaria, S. Jayaraman, N. Johns, J.B. Jonas, G. Karthikeyan, N. Kassebaum, N. Kawakami, A. Keren, J.P. Khoo, C.H. King, L.M. Knowlton, O. Kobusingye, A. Koranteng, R. Krishnamurthi, R. Lalloo, L.L. Laslett, T. Lathlean, J.L. Leasher, Y.Y. Lee, J. Leigh, S.S. Lim, E. Limb, J.K. Lin, M. Lipnick, S.E. Lipshultz, W. Liu, M. Loane, S.L. Ohno, R. Lyons, J. Ma, J. Mabweijano, M.F. MacIntyre, R. Malekzadeh, L. Mallinger, S. Manivannan, W. Marcenes, L. March, D.J. Margolis, G.B. Marks, R. Marks, A. Matsumori, R. Matzopoulos, B.M. Mayosi, J.H. McAnulty, M.M. McDermott, N. McGill, J. McGrath, M.E. Medina-Mora, M. Meltzer, G.A. Mensah, T.R. Merriman, A.C. Meyer, V. Miglioli, M. Miller, T.R. Miller, P.B. Mitchell, A.O. Mocumbi, T.E. Moffitt, A.A. Mokdad, L. Monasta, M. Montico, M. Moradi-Lakeh, A. Moran, L. Morawska, R. Mori, M.E. Murdoch, M.K. Mwaniki, K. Naidoo, M.N. Nair, L. Naldi, K.M. Narayan, P.K. Nelson, R.G. Nelson, M.C. Nevitt, C.R. Newton, S. Nolte, P. Norman, R. Norman, M. O’Donnell, S. O’Hanlon, C. Olives, S.B. Omer, K. Ortblad, R. Osborne, D. Ozgediz, A. Page, B. Pahari, J.D. Pandian, A.P. Rivero, S.B. Patten, N. Pearce, R.P. Padilla, F. Perez-Ruiz, N. Perico, K. Pesudovs, D. Phillips, M.R. Phillips, K. Pierce, S. Pion, G.V. Polanczyk, S. Polinder, C.A. Pope 3rd, S. Popova, E. Porrini, F. Pourmalek, M. Prince, R.L. Pullan, K.D. Ramaiah, D. Ranganathan, H. Razavi, M. Regan, J.T. Rehm, D.B. Rein, G. Remuzzi, K. Richardson, F.P. Rivara, T. Roberts, C. Robinson, F.R. De Leòn, L. Ronfani, R. Room, L.C. Rosenfeld, L. Rushton, R.L. Sacco, S. Saha, U. Sampson, L. Sanchez-Riera, E. Sanman, D.C. Schwebel, J.G. Scott, M. Segui-Gomez, S. Shahraz, D.S. Shepard, H. Shin, R. Shivakoti, D. Singh, G.M. Singh, J.A. Singh, J. Singleton, D.A. Sleet, K. Sliwa, E. Smith, J.L. Smith, N.J. Stapelberg, A. Steer, T. Steiner, W.A. Stolk, L.J. Stovner, C. Sudfeld, S. Syed, G. Tamburlini, M. Tavakkoli, H.R. Taylor, J.A. Taylor, W.J. Taylor, B. Thomas, W.M. Thomson, G.D. Thurston, I.M. Tleyjeh, M. Tonelli, J.A. Towbin, T. Truelsen, M.K. Tsilimbaris, C. Ubeda, E.A. Undurraga, M.J. van der Werf, J. van Os, M.S. Vavilala, N. Venketasubramanian, M. Wang, W. Wang, K. Watt, D.J. Weatherall, M.A. Weinstock, R. Weintraub, M.G. Weisskopf, M.M. Weissman, R.A. White, H. Whiteford, S.T. Wiersma, J.D. Wilkinson, H.C. Williams, S.R. Williams, E. Witt, F. Wolfe, A.D. Woolf, S. Wulf, P.H. Yeh, A.K. Zaidi, Z.J. Zheng, D. Zonies, A.D. Lopez, C.J. Murray, M.A. AlMazroa, Z.A. Memish, Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2163–2196 (2012)CrossRef
5.
A. Festa, K. Williams, R. D’Agostino Jr, L.E. Wagenknecht, S.M. Haffner, The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 55, 1114–1120 (2006)CrossRef
6.
E.E. Blaak, Fatty acid metabolism in obesity and type 2 diabetes mellitus. Proc. Nutr. Soc. 62, 753–760 (2003)CrossRef
7.
G. Boden, Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 111, 121–124 (2003)CrossRef
8.
J.D. McGarry, Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51, 7–18 (2002)CrossRef
9.
M. Rasouli, A.M. Kiasari, V. Mokhberi, The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease. Clin. Chem. Lab. Med 44, 1015–1021 (2006)PubMed
10.
G. Walldius, A.H. Aastveit, I. Jungner, Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J. Intern. Med. 259, 259–266 (2006)CrossRef
11.
G.P. Carnevale Schianca, R. Pedrazzoli, S. Onolfo, E. Colli, E. Cornetti, L. Bergamasco, G.P. Fra, E. Bartoli, ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk. Nutr Metab Cardiovasc Dis 21, 406–411 (2011)CrossRef
12.
O. Ben Ounis, M. Elloumi, E. Makni, H. Zouhal, M. Amri, Z. Tabka, G. Lac, Exercise improves the ApoB/ApoA-I ratio, a marker of the metabolic syndrome in obese children. Acta Paediatr. 99, 1679–1685 (2010)CrossRef
13.
X. Ying, Y. Qian, Y. Jiang, Z. Jiang, Z. Song, C. Zhao, Association of the apolipoprotein B/apolipoprotein A-I ratio and low-density lipoprotein cholesterol with insulin resistance in a Chinese population with abdominal obesity. Acta Diabetol. 49, 465–472 (2012)CrossRef
14.
J. Sierra-Johnson, A. Romero-Corral, V.K. Somers, F. Lopez-Jimenez, G. Walldius, A. Hamsten, M.L. Hellénius, R.M. Fisher, ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. Eur. Heart J. 28, 2637–2643 (2007)CrossRef
15.
S. Zheng, T. Han, H. Xu, H. Zhou, X. Ren, P. Wu, J. Zheng, L. Wang, M. Zhang, Y. Jiang, Y. Chen, H. Qiu, W. Liu, Y. Hu, Associations of apolipoprotein B/apolipoprotein A-I ratio with pre-diabetes and diabetes risks: a cross-sectional study in Chinese adults. BMJ Open 7, e014038 (2017)CrossRef
16.
Y. Mao, Y. Xu, L. Lu, The nonlinear association between apolipoprotein B to apolipoprotein A1 ratio and type 2 diabetes. Medicine 96, e5834 (2017)CrossRef
17.
S. Wu, S. An, W. Li, A.H. Lichtenstein, J. Gao, P.M. Kris-Etherton, Y. Wu, C. Jin, S. Huang, F.B. Hu, X. Gao, Association of trajectory of cardiovascular health score and incident cardiovascular disease. JAMA Netw. Open 2, e194758 (2019)CrossRef
18.
D.S. Nagin, Group-based trajectory modeling: an overview. Ann. Nutr. Metab. 65, 205–210 (2014)CrossRef
19.
D.S. Nagin, B.L. Jones, V.L. Passos, R.E. Tremblay, Group-based multi-trajectory modeling. Stat. Methods Med. Res. 27, 2015–2023 (2018)CrossRef
20.
J. Elmer, B.L. Jones, D.S. Nagin, Using the Beta distribution in group-based trajectory models. BMC Med. Res. Methodol. 18, 152 (2018)CrossRef
21.
L. Gao, Y. Zhang, X. Wang, H. Dong, Association of apolipoproteins A1 and B with type 2 diabetes and fasting blood glucose: a cross-sectional study. BMC Endocr. Disord. 21, 59 (2021)CrossRef
22.
M.H. Seo, J.C. Bae, S.E. Park, E.J. Rhee, C.Y. Park, K.W. Oh, S.W. Park, S.W. Kim, W.Y. Lee, Association of lipid and lipoprotein profiles with future development of type 2 diabetes in nondiabetic Korean subjects: a 4-year retrospective, longitudinal study. J. Clin. Endocrinol. Metab 96, E2050–E2054 (2011)CrossRef
23.
Y.C. Chou, S.L. You, C.H. Bai, Y.C. Liao, C.Y. Wei, C.A. Sun, Utility of apolipoprotein measurements in predicting incident type 2 diabetes: a Chinese cohort study. J. Formos. Med. Assoc. 119, 51–58 (2020)CrossRef
24.
M.Y. Donath, S.E. Shoelson, Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11, 98–107 (2011)CrossRef
25.
T. Reinehr, C.L. Roth, Inflammation markers in type 2 diabetes and the metabolic syndrome in the pediatric population. Curr. Diab. Rep. 18, 131 (2018)CrossRef
26.
K.C. Sung, S. Ryu, J.W. Sung, Y.B. Kim, Y.S. Won, D.S. Cho, S.H. Kim, A. Liu, Inflammation in the prediction of type 2 diabetes and hypertension in healthy adults. Arch. Med. Res. 48, 535–545 (2017)CrossRef
27.
K. Rehman, M. Akash, A. Liaqat, S. Kamal, M.I. Qadir, A. Rasul, Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus. Crit. Rev. Eukaryot. Gene Expr. 27, 229–236 (2017)CrossRef
28.
M. Akash, K. Rehman, A. Liaqat, Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J. Cell. Biochem. 119, 105–110 (2018)CrossRef
29.
S. Kashima, K. Inoue, M. Matsumoto, K. Akimoto, White blood cell count and C-reactive protein independently predicted incident diabetes: yuport medical checkup center study. Endocr. Res. 44, 127–137 (2019)CrossRef
30.
Y. Xu, Z. Zhao, X. Li, Y. Bi, M. Xu, G. Ning, Relationships between C-reactive protein, white blood cell count, and insulin resistance in a Chinese population. Endocrine 39, 175–181 (2011)CrossRef
31.
G. Twig, A. Afek, A. Shamiss, E. Derazne, D. Tzur, B. Gordon, A. Tirosh, White blood cells count and incidence of type 2 diabetes in young men. Diabetes Care 36, 276–282 (2013)CrossRef
32.
A.D. Mooradian, Dyslipidemia in type 2 diabetes mellitus. Nat. Clin. Pract. Endocrinol. Metab. 5, 150–159 (2009)PubMed
33.
N. Esser, S. Legrand-Poels, J. Piette, A.J. Scheen, N. Paquot, Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res. Clin. Pract. 105, 141–150 (2014)CrossRef
34.
Z.Z. Wen, D.F. Geng, J.G. Luo, J.F. Wang, Combined use of high-sensitivity C-reactive protein and apolipoprotein B/apolipoprotein A-1 ratio prior to elective coronary angiography and oral glucose tolerance tests. Clin. Biochem. 44, 1284–1291 (2011)CrossRef
35.
A.M. Fritzen, J. Domingo-Espín, A.M. Lundsgaard, M. Kleinert, I. Israelsen, C.S. Carl, T.S. Nicolaisen, R. Kjøbsted, J.F. Jeppesen, J. Wojtaszewski, J.O. Lagerstedt, B. Kiens, ApoA-1 improves glucose tolerance by increasing glucose uptake into heart and skeletal muscle independently of AMPKα(2). Mol. Metab. 35, 100949 (2020)CrossRef
36.
Worldwide trends in diabetes since 1980, a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387, 1513–1530 (2016)CrossRef
37.
P.Z. Zimmet, D.J. Magliano, W.H. Herman, J.E. Shaw, Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol. 2, 56–64 (2014)CrossRef
38.
T. Kondo, M. Kishi, T. Fushimi, S. Ugajin, T. Kaga, Vinegar intake reduces body weight, body fat mass, and serum triglyceride levels in obese Japanese subjects. Biosci. Biotechnol. Biochem. 73, 1837–1843 (2009)CrossRef
39.
J. Wiltink, M. Michal, P.S. Wild, I. Zwiener, M. Blettner, T. Münzel, A. Schulz, Y. Kirschner, M.E. Beutel, Associations between depression and different measures of obesity (BMI, WC, WHtR, WHR). BMC Psychiatry 13, 223 (2013)CrossRef
Metadaten
Titel
Relationship between the ApoB/ApoA-I ratio trajectory and risk of type 2 diabetes in China: a retrospective cohort study
verfasst von
Tengfei Yang
Bo Zhao
Dongmei Pei
Publikationsdatum
15.01.2022
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2022
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-021-02961-1

Weitere Artikel der Ausgabe 1/2022

Endocrine 1/2022 Zur Ausgabe

Original Article

Hypertension outcomes of adrenalectomy for unilateral primary aldosteronism

Review

Minimally-invasive treatments for benign thyroid nodules: recommendations for information to patients and referring physicians by the Italian Minimally-Invasive Treatments of the Thyroid group

Original Article

Proteolytic activation of anti-Müllerian hormone is suppressed in adolescent girls

Original Article

Teriparatide administration by the Omnipod pump: preliminary experience from two cases with refractory hypoparathyroidism

Clinical Management of Endocrine Diseases

Spinal epidural lipomatosis: a rare and frequently unrecognized complication of Cushing syndrome

Original Article

The bidirectional relationship between metabolic syndrome and hyperuricemia in China: A longitudinal study from CHARLS

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise